Summary
To evaluate whether early administration of protease inhibitors could improve mortality and morbidity in acute pancreatitis (AP), we made a retrospective analysis of 23 patients with severe AP and 88 with mild to moderate AP who were treated in our institute and four affiliated medical centers during the 10-y period from 1980 to 1990. Intravenous infusion of a protease inhibitor, Gabexate Mesilate (FOY), was started within 24 h from onset of AP (early administration) in 17 patients with severe AP and 51 with mild to moderate AP. The remaining patients were put on FOY later than 24 h from onset of AP (late administration). Comparison of the mortality and morbidity between the two groups, early vs late administration of FOY, led to the following conclusions: (1) Early administration of FOY significantly improved mortality (29.4 vs 83.3%) in severe AP, although the improvement in mortality was not directly proportional to the shortening of the time lag between the onset of AP and the start of FOY, and (2) earlier administration of FOY brought about significantly earlier recovery of abdominal pain, hyperamylasemia, and leucocytosis in mild to moderate AP.
Similar content being viewed by others
References
Skyring A, Singer A, Tornya P. Treatment of acute pancreatitis with Trasylol: report of a controlled trial. Br. Med. J. 1965; 2: 627–629.
Trapnell JE, Talbot CH, Chir M, Capper WM. Trasylol in acute pancreatitis. Am. J. Dig. Dis. 1967; 12: 409–412.
Bachrach WH, Schild PD. A double-blind study of Trasylol in the treatment of pancreatitis. Ann. New York Acad. Sci. 1968; 146: 580–590.
Baden H, Jordal K, Lund F, Zachariae F. Prophylactic and curative action of Trasylol in pancreatitis. A double-blind trial. Scand. J. Gastroent. 1969; 4: 291–295.
Gauthier A, Gillet M, DiCostanzo J, Camelot G, Maurin P, Sarles H. Etude controllee multicentrique de laprotinine et du glucagon dans le traitement des pancreatites aiques. Gastroenterol. Clin. Biol. 1978; 2: 777–784.
Imrie CW, Benjamin IS, Ferguson JC, McKay AJ, Mackenzie I, O’Neill J, Blumgart LH. A single-centre double-blind trial of Trasylol therapy in primary acute pancreatitis. Br. J. Surg. 1978; 65: 337–341.
Medical Research Council Multicentre Trial. Morbidity of acute pancreatitis: the effect of aprotinin and glucagon. Gut 1980; 21: 334–339.
Balldin G, Borgstroem A, Genell S, Ohlsson K. The effect of peritoneal lavage and aprotinin in the treatment of severe acute pancreatitis. Res. Exp. Med. 1983; 183: 203–213.
Trapnell JE, Rigby CC, Talbot CH, Duncan EHL. A controlled trial of Trasylol in the treatment of acute pancreatitis. Br. J. Surg. 1974; 61: 177–182.
Freise J, Melzer P, Schmidt FW, Horbach L. Gabexat Mesilat in der Behandlung der akuten Pankreatitis. Ergebnisse der Hannoverschen multizentrischen Doppelblindstudie mit 50 Patienten. Z. Gastroenterol. 1986; 24: 200–211.
Yang CY, Chang-Chien CS, Liaw YF. Controlled trial of protease inhibitor Gabexate Mesilate (FOY) in the treatment of acute pancreatitis. Pancreas 1987; 2: 698–700.
McMahon MJ. Indices of severity of acute pancreatitis. Surgical Diseases of the Pancreas, Howard JM, Jordan GL, Reber HA, eds., Philadelphia, Lea & Febiger, 1987; pp. 412–425.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Harada, H., Miyake, H., Ochi, K. et al. Clinical trial with a protease inhibitor gabexate mesilate in acute pancreatitis. Int J Pancreatol 9, 75–79 (1991). https://doi.org/10.1007/BF02925581
Issue Date:
DOI: https://doi.org/10.1007/BF02925581